Pricing Log in Create free account
Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS
−61.5%
Free cash flow
−92.6%

Quarter to June 2026, against a year earlier

64.10 2.18 +3.52%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Vaxcyte, Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:13 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 6, 2026: 7 added · 10 removed · 46 modified; 8 with only figures updated

  1. Modified · ◦PCV Franchise Adult Indication:

    ▪VAX-31 is a 31-valent, broad-spectrum, carrier-sparing investigational PCV being developed for the prevention of IPD and pneumonia. VAX-31 is the broadest-spectrum PCV in the clinic, and has the potential to provide protection against both currently circulating and historically prevalent serotypes. VAX-31 was designed to increase coverage, in a single vaccine, to approximately 95% of IPD and approximately 88% of pneumococcal pneumonia circulating in adults in the United States aged 50 and older, with the potential to provide an incremental 14-3413-36% ofbroader coverage for IPD and an incremental 19-31% ofbroader coverage for pneumococcal pneumonia over current standard-of-care adult PCVs.